



UNITED STATES PATENT AND TRADEMARK OFFICE

CH
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/682,657	10/09/2003	Jack Polonka	J6860(C)	8243
201	7590	02/07/2007	EXAMINER	
UNILEVER INTELLECTUAL PROPERTY GROUP			LAMM, MARINA	
700 SYLVAN AVENUE, BLDG C2 SOUTH ENGLEWOOD CLIFFS, NJ 07632-3100			ART UNIT	PAPER NUMBER
			1617	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		02/07/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/682,657	POLONKA, JACK	
	Examiner Marina Lamm	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 02 October 2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-20 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-20 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. In view of the Appeal Brief filed on 10/2/06, PROSECUTION IS HEREBY REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

(1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,

(2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have been increased since they were previously paid, then appellant must pay the difference between the increased fees and the amount previously paid.

A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing below.

2. Claims pending are 1-20.

Double Patenting

3. Applicant is advised that should claim 6 be found allowable, claim 20 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing

one claim to object to the other as being a substantial duplicate of the allowed claim.

See MPEP § 706.03(k).

Claim Rejections - 35 USC § 103

4. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
5. Claims 1-3, 5-9, 11-13, 15-17, 19 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nagatani et al. (US 2002/0176833).

Nagatani et al. teach pigmented and non-pigmented cosmetic compositions containing 0.1-30% by wt. of hollow plate metal oxide particles A (e.g. zirconium oxide) having an average particle diameter of 5-12 μm and 0.01-99% by wt. of inorganic particles B (e.g. aluminum oxide, barium sulfate or boron nitride), having platy structure and a refractive index (RI) of 1.6 to 1.8 and a total transmittance of at least 85%. See [0016]-[0018], [0025], [0026], [0031], [0034], Examples. The compositions of Nagatani et al. have "an excellent feeling of transparency". See Abstract; Examples. The compositions contain other conventional cosmetic ingredients such as oil substances, antioxidants, moisturizers, surfactants, perfumes, etc. See [0049]-[0051]; Examples. Nagatani et al. does not explicitly teach the claimed opacity of the composition of less than about 20%. However, the compositions of Nagatani et al. have "an excellent feeling of transparency", "brightness" and "natural finish". See above. Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to determine an optimal or workable opacity of

the composition by routine experimentation. One having ordinary skill in the art would have been motivated to do this to obtain the desired transparency and natural finish of the composition as suggested by Nagatani et al. With respect to Claims 6 and 20, the reference does not explicitly teach the claimed particle thickness. However, determination of optimal or workable particle thickness by routine experimentation is obvious absent showing of criticality of the claimed parameter. One having ordinary skill in the art would have been motivated to do this to obtain the desired transparency and natural finish of the composition.

6. Claims 4, 10 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nagatani et al. (US 2002/0176833) in view of Dreher (US 2003/0157041), of record.

Nagatani et al. applied as above. Nagatani et al. do not teach bismuth oxychloride of Claims 4 and 18. However, Dreher teaches using plate-like bismuth oxychloride particles having an average particle size of 3-20 μm for the same purpose as boron nitride and barium sulfate powders of Nagatani et al. See [0010]. The compositions of Dreher provide soft, translucent glowing effect to the skin, which is due to the presence of the inorganic particles. See [0010]. Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the compositions of Nagatani et al. such that to use bismuth oxychloride particles instead of boron nitride or barium sulfate particles. One having ordinary skill in the art would have a reasonable expectation of obtaining the same cosmetic emollient

effect as set forth in the Nagatani et al. reference because these particles are used interchangeably for the same art-recognized purpose as suggested by Dreher. Selection of a known material based on its suitability for its intended use is obvious absent a clear showing of unexpected results attributable to the applicant's specific selection. See e.g., *In re Leshin*, 227 F.2d 197, 125 USPQ 416 (CCPA 1960). With respect to Claim 10, Nagatani et al. do not explicitly teach the particles suspended in a polar solvent prior to incorporation in the composition as claimed herein. However, Dreher teaches making optical make-up compositions for minimizing skin flaws by first suspending bismuth oxychloride and other inorganic particles in butylene glycol (polar solvent), then adding the mixture to the water (polar solvent) and pigments mixture; and then mixing the resulting water phase (with pigment particles suspended in it) with the oily phase. See Example 1 @ pp. 2-3. The compositions of Dreher, when applied to the skin, give a high feeling of transparency, hide imperfections and give natural feeling and appearance of the skin. See [0004]. Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to modify the teachings of Nagatani et al. such that to suspend their platelet particles in polar solvents before incorporating the particle into the composition. One having ordinary skill in the art would have been motivated to do this to obtain imperfection-concealing compositions having natural skin feel and appearance as suggested by Dreher.

7. Claims 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nagatani et al. (US 2002/0176833) in view of Tan et al. (US 6,511,672), of record.

Art Unit: 1617

Nagatani et al. applied as above. While teaching skin benefit agents, Nagatani et al. do not explicitly teach the specific benefit agents of the instant claim. However, Tan et al. teach skin benefit agents such as vitamins (e.g. vitamin A or retinol, vitamins C and E), skin lightening agents, alpha- or beta-hydroxy acids, etc. in skin imperfection-concealing compositions. See col. 7, lines 32-64. Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to modify the compositions of Nagatani et al. such that to employ retinol or other skin benefit agents of Tan et al. for their art-recognized purpose. One having ordinary skill in the art would have a reasonable expectation of beneficial results such as an antioxidant effect.

Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Response to Arguments

8. Applicant's arguments have been considered but are moot in view of the new ground(s) of rejection.

Conclusion


9. No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marina Lamm whose telephone number is (571) 272-0618. The examiner can normally be reached on Mon-Fri from 11am to 7pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, can be reached at (571) 272-0629.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Marina Lamm, M.S., J.D.
Patent Examiner
12/28/06



SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER